GEN Exclusives

More »

GEN News Highlights

More »
Sep 11, 2008

Link between Cholesterol Metabolism and Malaria Discovered

  • Cenix BioScience, Alnylam Pharmaceuticals, and the Instituto de Medicina Molecular (IMM) report finding a molecular connection between cholesterol metabolism and malaria infection. The team discovered and validated in vivo the scavenger receptor BI (SR-BI), a major regulator of cholesterol uptake by the liver, as a host factor for malaria infection.

    The investigators were evaluating a decade-old hypothesis that lipoprotein clearance pathways in the human host may somehow impact the infection of liver cells by malaria-causing Plasmodium parasites. SR-BI is well-known as the major liver receptor for HDL, where it plays a role in the transfer of cholesterol from the bloodstream to hepatocytes.

    They used a systematic RNAi screen of known lipoprotein pathway components in a cultured human cell-based infection assay.

    The research group reports also confirming their findings in animal models of malaria infection using siRNAs specific for SR-BI silencing. Additionally, the pathophysiological relevance of SR-BI's requirement for malaria infection was confirmed by a series of experiments using synthetic small molecule inhibitor compounds, blocking mAbs, SR-BI overexpression with transgenic mice, and SR-BI loss of function with knock-out mice, the team adds.

    SR-BI is a major liver receptor for HDL, where it plays a key role in the transfer of cholesterol from the bloodstream to hepatocytes.

    “The various SR-BI-inhibitor molecules demonstrated in this study as having anti-malarial activity, including siRNAs, small synthetic molecules, and antibodies, all represent interesting candidates for the development of novel prophylactic options,” notes Christophe Echeverri, Ph.D., CEO/CSO of Cenix. “Importantly, their equally novel host factor-based mechanism of action promises an inherently more powerful interventional strategy against the emergence of resistant strains of malarial parasites, as compared to existing parasite-targeted therapies.”

    The results appears in the September issue of Cell Host & Microbe.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Patients Access to Experimental Medicines?

More »